Jefferies Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Analyst Day: Controversial...Yet An Excellent Investment

June 22, 2012 10:54 AM EDT Send to a Friend
Get Alerts VRX Hot Sheet
Price: $132.87 +1.03%

Rating Summary:
    13 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 43 | New: 4
Trade VRX Now!
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Valeant Pharmaceuticals (NYSE: VRX) price target of $63.00 (from $75.00).

Analyst, Corey Davis, said, "After what we viewed as an excellent analyst day yesterday, VRX remains controversial ... yet an excellent investment -- especially after yesterday's weakness. For a company with >20% exposure in Europe, to actually reaffirm the UPPER end of its EPS guidance is a testament to the strength and durability of its business model. We now lower our PT for a more realistic market."

Raises FY12 EPS Estimate from $4.21 to $4.59, FY13 from $5.00 to $5.22 and FY14 from $5.95 to $5.89.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $45.23 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment